Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of intravenous immunoglobulins (IVIg) in inhibiting cholera toxin and galectin from being combined into ganglioside GM1

An immunoglobulin, ganglioside technology, applied in neurological diseases, drug combinations, antibodies, etc., can solve problems that have not been convincingly proven

Inactive Publication Date: 2013-03-06
CENT HOSPITAL XUHUI DISTRICT SHANGHAI CITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

More recently, it has been postulated that IVIg reduces anti-GM1 antibody-mediated complement deposition, however these mechanisms have not been convincingly demonstrated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of intravenous immunoglobulins (IVIg) in inhibiting cholera toxin and galectin from being combined into ganglioside GM1
  • Application of intravenous immunoglobulins (IVIg) in inhibiting cholera toxin and galectin from being combined into ganglioside GM1
  • Application of intravenous immunoglobulins (IVIg) in inhibiting cholera toxin and galectin from being combined into ganglioside GM1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] To explore the mechanism of action of IVIg in anti-GM1 antibody-associated diseases, we tested two hypotheses: (i) anti-idiotypic antibodies are present in different IVIg preparations; (ii) using flow cytometry, IVIg inhibits cholera toxin and semi Laclectin-1 binds to GM1-expressing cells.

[0018] Materials and methods

[0019] 1.1. Reagents and cell lines

[0020] Three different products of human intravenous immunoglobulin (IVIg) (50 mg / ml): Sandoglobuline (Novartis, Rueil Malmaison, France), Tegeline (LFB, Paris, France) and Endoglobuline (Baxter, Maurepas, France) were used. F(ab') 2 IVIg formulations were provided by Srini V. Kaveri (INSERM U430, Paris, France). Monosialylganglioside GM1 purified from bovine brain was purchased from Sigma (St Quentin Fallavier, France) and dissolved in methanol. The high-affinity GM1-specific ligand biotin-based cholera toxin β-subunit (0.5 mg / l) was purchased from Sigma (St Quentin Fallavier, France). Human biotinylated ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of intravenous immunoglobulins (IVIg) in preparing a medicament for treating autoimmune diseases of a peripheral nervous system, the autoimmune diseases are related ganglioside GM1 antibody diseases, and the IVIg is used for treating the related ganglioside GM1 antibody diseases by inhibiting cholera toxin and galectin from being combined into ganglioside GM1. The advantages are as follows: the research finds that the IVIg can not inhibit the combination of the GM1 antibody with the antigen thereof and the GM1 antibody titer is not reduced, the inhibition of the IVIg on the combination of the cholera toxin and galectin into the GM1 can be displayed; and put forward in a first time, galactosyl / non-galactosyl immune globulin with correction rate in the IVIg are mutually acted on a macrophage receptor, so that the inflammation functions of autoimmune disease of macrophage and a peripheral nervous system can be reduced.

Description

technical field [0001] The invention relates to the field of treatment of autoimmune diseases of the peripheral nervous system, in particular, intravenous injection of immunoglobulin inhibits the combination of cholera toxin and galectin-1 to ganglioside GM1. Background technique [0002] Intravenous immunoglobulin (IVIg) for some neurological autoimmune diseases, including multifocal motor neuropathy (MMN), lower motor neuropathy without conduction block (LMN), acute Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multiple Sexual sclerosis (multiple sclerosis, MS). Intravenous immunoglobulins pool the normal polyspecific IgG production and may act on immune-mediated diseases through various mechanisms, depending on their Fab or Fc moiety, such as the effects of anti-idiotypic antibodies or Fc receptor blockade . [0003] MMN, LMN and AM??AN are frequ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P25/00A61P25/28A61P37/02
Inventor 彭伟
Owner CENT HOSPITAL XUHUI DISTRICT SHANGHAI CITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com